A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR

This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are
safe and whether they will boost immune responses generated by immunizations with a
dendritic cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy
HIV-uninfected volunteers. Investigators propose to assess the quality of immunity elicited
by immunizations with MVA-CMDR only or by booster immunizations with MVA-CMDR in volunteers
previously immunized with a DC-targeted HIV vaccine. This vaccination regimen can provide
the proof-of-concept that DC targeted protein vaccines can prime strong immune responses and
therefore be valuable in combination with other vaccine modalities against HIV or other
diseases.

Inclusion Criteria:

- Have completed protocol SSC-710 and received either DCVax-001 plus poly ICLC, poly
ICLC only or sterile saline. If less than 6 volunteers who originally received
placebo (poly ICLC only or sterile saline) under protocol SSC_710 are willing to
participate and are found eligible to participate in this proposed study, new
volunteers can be enrolled as long as they are eligible according to the remaining
inclusion and exclusion criteria below.

- Healthy adult males and females, as assessed by a medical history, physical exam,
ECG, and laboratory tests;

- Age of at least 18 years of age on the day of screening and no greater than 62 years
at time of vaccination;

- Willing to comply with the requirements of the protocol and available for follow-up
for the planned duration of the study (screening plus 12 months);

- In the opinion of the principal investigator or designee, has understood the
information provided. (Written informed consent needs to be given before any
study-related procedures are performed);

- Amenable to HIV risk reduction counseling, committed to maintaining behavior
consistent with low risk of HIV exposure through the last required protocol clinic
visit;

- Assessed by the clinic staff as being at "low risk" for HIV infection on the basis of
sexual behaviors within the 12 months prior to enrollment defined as follows:

- Sexually abstinent OR

- Had two or fewer mutually monogamous relationships with partners believed to be
HIV-uninfected and who did not use illicit drugs (illicit drug use or abuse that
includes any injection drugs, methamphetamines (crystal meth), heroin, cocaine,
including crack cocaine or chronic marijuana abuse) OR

- Had two or fewer partners believed to be HIV-uninfected and who did not use illicit
drugs (as defined above) and with whom he/she regularly used condoms for vaginal and
anal intercourse;

- If sexually active female, willing to use one effective method of contraception
(combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine
Device (IUD); condoms; anatomical sterility in self or partner) at least until 3
months after last immunization. All female volunteers must be willing to undergo
urine pregnancy tests at time points as indicated in the Schedule of Procedures.

Exclusion Criteria:

- Confirmed HIV-1 or HIV-2 infection

- Any clinically significant abnormality on history or examination including history of
immunodeficiency or autoimmune disease; use of systemic corticosteroids
immunosuppressive anticancer, or other medications considered significant by the
trial physician within the last 6 months

- Any clinically significant acute or chronic medical condition requiring care of a
physician (e.g., diabetes, coronary artery disease, myopericarditis, grand-mal
epilepsy, rheumatologic illness, malignancy, substance abuse) that in the opinion of
the investigator would preclude participation

- History of clinically significant eczema or chronic urticaria

- Any laboratory value outside of reference range, with the exception of any
non-clinically significant Grade I elevations of liver function tests (AST, ALT,
direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined
by the Principal Investigator or his designee

- Baseline ECG with features that would interfere with interpretation of
myo/pericarditis including significant repolarization abnormality, bundle branch
block, and AV block

- Within the 12 months prior to enrollment, the volunteer has had excessive daily
alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of
illicit drugs

- Within the 12 months prior to enrollment, the volunteer has a history of
newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus
type 2 (HSV2), pelvic inflammatory disease (PID), mucopurulent cervicitis,
epididymitis, proctitis, lymphogranuloma venereum, chancroid, hepatitis B (surface
antigen, HbsAg) or hepatitis C (HCV antibodies);

- If female, pregnant, planning a pregnancy during the 3-month follow up period after
last immunization, or lactating

- Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days
prior to study vaccination

- Prior use of medications for HIV PrEP

- Receipt of an investigational product (not vaccine-related) within the last 12
months. Receipt of a non-HIV experimental vaccine(s) within the last 5 years in a
prior vaccine trial. Exceptions may be made for vaccines that have subsequently
undergone licensure by the FDA. For subjects who have received control/placebo in an
experimental vaccine trial, or who have received an experimental vaccine(s) greater
than 5 years ago, eligibility for enrollment will be determined by the investigators
on a case-by-case basis.

- History of severe local or systemic reaction to vaccination defined as:

- Local: extensive, indurated redness and swelling involving most of the major
circumference of the arm, not resolving within 72 hours;

- Systemic: fever > 39.5°C within 48 hours, anaphylaxis, bronchospasm, laryngeal edema,
circulatory collapse, convulsions or encephalopathy within 72 hours

- History of immediate type hypersensitivity reaction to eggs or egg products

- Major psychiatric illness

- In the opinion of the investigator, unlikely to comply with protocol